Following on from the grant awarded into Stem Cell research, which has just entered its second year, we are delighted to announce approval of a second funding stream to researchers from the University Hospital, Southampton.
Year one funding of £35,839 will allow this research, led by Dr. Pardis Arvinrad, to commence in November 2016 and will last for a period of 32 months subject to continuation following an annual review.
This grant is to enable Dr Arvinrad to commence the research with the objective of delivering the following outcomes:
1. identify biomarkers of metastatic[1] pancreatic cancer – most forms of cancer have a blood test or other indicator of the early signs – pancreatic cancer currently doesn’t
2. discover new drugs for the treatment of metastatic pancreatic cancer – at present there are no drugs that only target pancreatic cancer cells whereas there are for liver and breast cancer for example
The research will begin with an analysis of human material from 100 Pancreatic Cancer patients to identify potential biomarkers of metastasis with the focus on earlier observations on liver and breast cancers.
This a particularly exciting research project that aims to detect early warning signs of the cancer and develop drug treatments that can help patients.
Regular updates on the research programme will be provided via our website and Charity Newsletters.
[1] Metastasis is the spread of a cancer or other disease from one organ or part of the body to another without being directly connected with it.
Year one funding of £35,839 will allow this research, led by Dr. Pardis Arvinrad, to commence in November 2016 and will last for a period of 32 months subject to continuation following an annual review.
This grant is to enable Dr Arvinrad to commence the research with the objective of delivering the following outcomes:
1. identify biomarkers of metastatic[1] pancreatic cancer – most forms of cancer have a blood test or other indicator of the early signs – pancreatic cancer currently doesn’t
2. discover new drugs for the treatment of metastatic pancreatic cancer – at present there are no drugs that only target pancreatic cancer cells whereas there are for liver and breast cancer for example
The research will begin with an analysis of human material from 100 Pancreatic Cancer patients to identify potential biomarkers of metastasis with the focus on earlier observations on liver and breast cancers.
This a particularly exciting research project that aims to detect early warning signs of the cancer and develop drug treatments that can help patients.
Regular updates on the research programme will be provided via our website and Charity Newsletters.
[1] Metastasis is the spread of a cancer or other disease from one organ or part of the body to another without being directly connected with it.
